PharmExec articleshttps://www.pharmexec.com/newsPharmExec articles© 2026 MJH Life Sciences™ and PharmExec. All rights reserved.Sun, 04 Oct 2026 21:36:08 +00005en-us14447https://www.pharmexec.com/newshttps://www.pharmexec.com/logo.webphttps://www.pharmexec.com/view/daily-foghorn-therapeutics-eli-lilly-discontinue-development-fhd-909https://www.pharmexec.com/view/daily-foghorn-therapeutics-eli-lilly-discontinue-development-fhd-909<![CDATA[Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.]]>Fri, 02 Oct 2026 19:43:40 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/foghorn-eli-lilly-halt-fhd-909-developmenthttps://www.pharmexec.com/view/foghorn-eli-lilly-halt-fhd-909-development<![CDATA[Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy. ]]>Fri, 02 Oct 2026 14:07:16 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/novartis-abogen-licensing-astrazeneca-daiichi-sankyo-collaboration-summit-therapeuticshttps://www.pharmexec.com/view/novartis-abogen-licensing-astrazeneca-daiichi-sankyo-collaboration-summit-therapeutics<![CDATA[Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics. ]]>Fri, 02 Oct 2026 13:29:53 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/how-shift-towards-oral-medications-impacts-glp1https://www.pharmexec.com/view/how-shift-towards-oral-medications-impacts-glp1<![CDATA[CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.]]>Fri, 02 Oct 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-approves-expanded-indication-camzyoshttps://www.pharmexec.com/view/daily-fda-approves-expanded-indication-camzyos<![CDATA[Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.]]>Thu, 01 Oct 2026 18:53:07 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-expanded-indication-camzyos-symptomatic-obstructive-hypertrophic-cardiomyopathyhttps://www.pharmexec.com/view/fda-approves-expanded-indication-camzyos-symptomatic-obstructive-hypertrophic-cardiomyopathy<![CDATA[FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12. ]]>Thu, 01 Oct 2026 14:05:45 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/regeneron-sanofi-expand-antibody-alliance-four-new-drugshttps://www.pharmexec.com/view/regeneron-sanofi-expand-antibody-alliance-four-new-drugs<![CDATA[Regeneron and Sanofi are expanding their two-decade antibody alliance to co-develop four new long-acting immunology antibodies in a deal worth up to $8 billion. ]]>Thu, 01 Oct 2026 13:38:42 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/rising-employer-healthcare-costs-digital-health-consolidation-unproven-savings-claims-michael-abramshttps://www.pharmexec.com/view/rising-employer-healthcare-costs-digital-health-consolidation-unproven-savings-claims-michael-abrams<![CDATA[Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.]]>Thu, 01 Oct 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/next-chapter-metabolic-drug-developmenthttps://www.pharmexec.com/view/next-chapter-metabolic-drug-development<![CDATA[CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.]]>Thu, 01 Oct 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/mrd-testing-becoming-most-important-tool-oncology-drug-development-eric-matthewshttps://www.pharmexec.com/view/mrd-testing-becoming-most-important-tool-oncology-drug-development-eric-matthews<![CDATA[MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.]]>Thu, 01 Oct 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/from-engagement-to-enterprise-value-reframing-community-as-a-growth-segmenthttps://www.pharmexec.com/view/from-engagement-to-enterprise-value-reframing-community-as-a-growth-segment<![CDATA[Community engagement is a powerful tool but its impact depends on how it is done. When it begins early, is sustained over time, and is built through organizations and individuals communities already trust, it can expand access to historically overlooked and medically underserved populations worldwide. The result is more representative science, stronger participation across the drug-development lifecycle, and a sustainable pathway to commercial growth. Inside Edge’s proprietary global Trustmaker Network turns trusted community relationships into meaningful action helping people make informed health decisions while delivering measurable outcomes across R&amp;D and commercial.]]>Wed, 30 Sep 2026 17:19:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-peptide-ruling-stallshttps://www.pharmexec.com/view/daily-peptide-ruling-stalls<![CDATA[Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.]]>Wed, 30 Sep 2026 16:59:33 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/a-leadership-call-to-action-for-biotechhttps://www.pharmexec.com/view/a-leadership-call-to-action-for-biotech<![CDATA[Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.]]>Wed, 30 Sep 2026 14:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/novo-data-weight-loss-switch-oral-semaglutide-pillhttps://www.pharmexec.com/view/novo-data-weight-loss-switch-oral-semaglutide-pill<![CDATA[Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.]]>Wed, 30 Sep 2026 13:26:59 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/how-employers-can-reduce-healthcare-costshttps://www.pharmexec.com/view/how-employers-can-reduce-healthcare-costs<![CDATA[Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.]]>Wed, 30 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/life-sciences-compliance-diagnosis-incompletehttps://www.pharmexec.com/view/life-sciences-compliance-diagnosis-incomplete<![CDATA[Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.]]>Wed, 30 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fabrice-chouraqui-steps-down-ceo-pharminghttps://www.pharmexec.com/view/daily-fabrice-chouraqui-steps-down-ceo-pharming<![CDATA[New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.]]>Tue, 29 Sep 2026 18:38:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/new-us-guidance-lays-out-exemptions-100-tariffs-reporthttps://www.pharmexec.com/view/new-us-guidance-lays-out-exemptions-100-tariffs-report<![CDATA[New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries. ]]>Tue, 29 Sep 2026 17:00:28 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/the-cfo-as-the-enterprise-decision-engine-why-pharma-finance-functions-are-being-rebuilt-and-what-the-next-24-months-demandhttps://www.pharmexec.com/view/the-cfo-as-the-enterprise-decision-engine-why-pharma-finance-functions-are-being-rebuilt-and-what-the-next-24-months-demand<![CDATA[Pharma CFOs are navigating an increasingly complex business environment. From portfolio investments and pricing pressure to manufacturing strategy and AI adoption, the pace and stakes of decision-making continue to rise. The organizations pulling ahead are the ones that rely on finance as an enterprise decision engine—using data, insight, and judgment to help the business allocate capital more effectively, respond faster to change, and create long-term value.]]>Tue, 29 Sep 2026 14:40:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/ceo-fabrice-chouraqui-steps-downhttps://www.pharmexec.com/view/ceo-fabrice-chouraqui-steps-down<![CDATA[Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs. ]]>Tue, 29 Sep 2026 14:08:44 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/roundup-hengrui-novo-license-agreement-hrs-1596-astrazeneca-collaboartion-summit-therapeuticshttps://www.pharmexec.com/view/roundup-hengrui-novo-license-agreement-hrs-1596-astrazeneca-collaboartion-summit-therapeutics<![CDATA[Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.]]>Tue, 29 Sep 2026 13:41:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/evidence-gaps-digital-health-platforms-still-need-closehttps://www.pharmexec.com/view/evidence-gaps-digital-health-platforms-still-need-close<![CDATA[Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.]]>Tue, 29 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/-peptide-rulemaking-stalls-fda-enforcement-moveshttps://www.pharmexec.com/view/-peptide-rulemaking-stalls-fda-enforcement-moves<![CDATA[While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action. ]]>Tue, 29 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-merck-acquires-spr2015-2-billion-licensing-dealhttps://www.pharmexec.com/view/daily-merck-acquires-spr2015-2-billion-licensing-deal<![CDATA[Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.]]>Mon, 28 Sep 2026 20:00:38 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/merck-licenses-preclinical-kras-g12d-inhibitor-scibrunchhttps://www.pharmexec.com/view/merck-licenses-preclinical-kras-g12d-inhibitor-scibrunch<![CDATA[Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. ]]>Mon, 28 Sep 2026 17:28:49 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-olumiant-juvmo-atebriozhttps://www.pharmexec.com/view/fda-approves-olumiant-juvmo-atebrioz<![CDATA[FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.]]>Mon, 28 Sep 2026 17:02:55 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/compounding-crossroads-safety-standards-industry-best-defensehttps://www.pharmexec.com/view/compounding-crossroads-safety-standards-industry-best-defense<![CDATA[Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.]]>Mon, 28 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/your-questions-answered-two-fda-approvals-six-platform-deals-and-aeuropean-warninghttps://www.pharmexec.com/view/your-questions-answered-two-fda-approvals-six-platform-deals-and-aeuropean-warning<![CDATA[Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.]]>Mon, 28 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/consolidation-can-improve-digital-employer-covered-healthcare-platformshttps://www.pharmexec.com/view/consolidation-can-improve-digital-employer-covered-healthcare-platforms<![CDATA[Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.]]>Mon, 28 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/high-value-freight-in-a-changing-risk-environmenthttps://www.pharmexec.com/view/high-value-freight-in-a-changing-risk-environment<![CDATA[High-value freight is moving through a more complex risk environment. This whitepaper explores how tighter capacity, rising cargo theft severity, freight fraud, and greater liability scrutiny are reshaping transportation strategy. It also outlines a modern approach to carrier assessment, risk-based controls, and balancing capacity with accountability for shippers of critical, high-consequence freight.]]>Mon, 28 Sep 2026 04:59:00 GMTPharmExecusPharmExec Articles